GLP-1 drugsReview

Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors

Figure 1 from European Journal of Internal Medicine — Figure 1Mayne et al.

European Journal of Internal Medicine

The paper

Kaitlin J. Mayne, Matthew M.Y. Lee, Naveed A. Sattar, William Guy Herrington

University of Glasgow · University of Oxford

European Journal of Internal Medicine · 24 Sep 2026

doi.org/10.1016/j.ejim.2026.107193 PubMed 42786044

GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026